Flush-Free Niacin 250 mg

Flush-Free Niacin 250 mg

NOW4.6 (2,363 ratings)
Format:Capsule Quantity: 180 Capsule(s) · 90 servings
$16.20 $0.18 per serving

About this product

The formula appears intended for users who want vitamin B3 without the usual nicotinic-acid flush. Inositol is included, but the label data do not identify inositol hexanicotinate or another specific no-flush compound.

The product name and the listed vitamin B3 amount do not agree. That inconsistency makes it difficult to know how much active niacin the serving actually provides.

Flush-free forms may suit tolerance-first supplementation, but they should not be assumed to act like nicotinic acid for cardiovascular goals. Clearer form and dose disclosure would be needed for a stronger recommendation.

Who is it for
  • Adults seeking a lower-flush niacin option
  • Users willing to confirm the current label
  • People focused on general B3 intake
Best for
  • Tolerance-first niacin use
  • Niacin plus inositol routines
  • Users avoiding a strong flush

Pros

  • Includes inositol
  • Designed around lower-flush use
  • Convenient capsule format

Cons

  • No-flush compound is not clearly named
  • Product name and label amount conflict
  • Cardiovascular relevance is uncertain

Warnings

  • Confirm the serving amount because the product name and supplied ingredient line do not match.
  • Do not assume a flush-free form provides the same lipid-related effects as nicotinic acid.
  • The large listed vitamin B3 amount may still cause digestive or liver-related effects during prolonged use.

Product analysis

74 out of 100
A tolerance-focused niacin product with unclear form identity and conflicting dose information. Its heart and skin value is difficult to judge from the supplied label.

AI assessment of the formula, label and price. How scoring works

Nutrient quality72

Flush-free positioning suggests an inositol-bound form, but the exact compound is not identified. The stated niacin amount is substantial for a no-flush formula.

.
Ingredient transparency71

The core amount is shown, but parts of the active labeling remain ambiguous. The supplied data does not include a complete inactive ingredient list.

.
Customer satisfaction69

The aggregate satisfaction measure is strong and supported by adequate volume. Missing feedback themes leave recurring complaints and purpose fit uncertain.

.
Value for money82

The price is reasonable for the formula quality and dose. Each serving provides good cost efficiency.

.
Format
Capsule
Container
180 Capsule(s)
Per serving
$0.18
Customer rating
4.6 · 2,363 ratings
Report analysis

Ingredients

IngredientAmount per servingScore
Niacin (Vitamin B3)
500 mg 73
Inositol
135 mg
Gluten Free Adults 18–50 Vegan Dairy Free Vegetarian
Report overview
Niacin (Vitamin B3) · 500 mg OverallScore73
C- Active Ingredient Quality & BioavailabilityB Dose, Safety & Label TransparencyA+ Value
Flush-Free Niacin 250 mg lists 500 mg of inositol hexanicotinate per serving and labels the product as flush-free. The saved facts don't translate that compound mass into a niacin amount. The form is clear, and the cost per serving is low.
How this ingredient is rated

Active Ingredient Quality & Bioavailability57

The form is named, but the saved facts don't identify a cardiovascular goal or enhanced source.
Niacin Form & Goal Alignment
Inositol hexanicotinate is the named form; no cardiovascular goal is recorded in the saved facts.
Precursor Source Quality
The label gives no branded source or purity detail for inositol hexanicotinate.

Dose, Safety & Label Transparency75

The form and total compound amount are clear, but niacin yield is not stated.
Clarity of Chemical Form
The label identifies inositol hexanicotinate.
Form-Specific Dosage Efficacy
The 500 mg is the compound amount; the saved facts don't convert it to a niacin amount.
Flush Risk & Safety Labeling
The product name explicitly says “Flush-Free.”

Value100

The cost is low for the listed serving.
Price Per Effective Serving
The per-serving cost is low.
Loading alternative details
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  8. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  9. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  10. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  11. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin